Video

Final Thoughts on AML and ALL

For High-Definition, Click

Acute myeloid leukemia (AML) is a relatively uncommon disease, Jeffrey Lancet, MD, states. Given its rarity, more individuals with AML should enroll in clinical trials in order to advance care.

The increasing use of minimal residual disease assessment to identify individuals with high-risk B-cell acute lymphoblastic leukemia (ALL) may provide benefit for patients in a disease that has been stalled in the adult setting for so many years, comments Mark R. Litzow, MD.

Dan Douer, MD, adds that novel treatment modalities that harness the patient’s own immune system rather than a donor’s immune system lie in the future of ALL management.

Raoul Tibes, MD, recommends that future practice include intensified pediatric regimens in young adults and incorporate new targeted therapies, such as blinatumomab, to achieve longer remissions.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Proactive Adverse Event Management for HER2+ BTC Treatments
Video

Proactive Adverse Event Management for HER2+ BTC Treatments

May 8th 2025 - May 9th 2026

online-activity
Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina
Video

Community Oncology Connections™: Contextualizing Novel Immunotherapy for Advanced Melanoma – How Do TIL Therapies Fit into Practice? | North Carolina

May 2nd 2025 - Jun 7th 2025

online-activity
Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments | Kansas
Video

Community Oncology Connections™: Navigating Early-Stage HR+/HER2- Breast Cancer – Clinical Developments and Innovative Treatments | Kansas

May 1st 2025 - Jun 6th 2025

online-activity